Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2006

View Archived Issues

Neuroprotective effects of a component of the perineuronal net

Intravail increases intranasal bioavailability in first clinical study

ConjuChem places DAC:GRF program in HIV lipodystrophy on clinical hold

Memory achieves preclinical milestones in Roche collaboration

Lpath first to generate functional antibodies against LPA

Fast track designation for intravenous methylnaltrexone in postoperative ileus

BioProgress completes acquisition of Segix Farma

BioLineRx inlicenses orally available peptide for treatment of obesity

Positive results for PT-502 in animal model for antidepressant activity

Enzo cleared for phase II study of EGS-21 in NASH

Crucell suspends further development of Aerugen

Enrollment under way in phase I study of INNO-406 in leukemias

BioDelivery Sciences submits Emezine study plans to FDA

TH-070 fails to meet endpoint in BPH phase II and phase III trials

Cimzia shows potential in psoriasis

GM-CSF enhances immune response to melanoma vaccine Vaccimel

Analyses point to mycophenolate mofetil efficacy in lupus nephritis

CNRS present new data on BACE1 inhibition by JMV-2764

Zelapar for Parkinson's disease now available

GSK profile GSK-189254 at ICAD meeting

Chemically programmed antibodies: a potential new class of antitumor agents

New dopamine D3 receptor antagonist shows antipsychotic activity lacking D2-related side effects

Positive in vitro safety profile of beta-secretase inhibitors from LG Life Sciences

New therapeutic strategies for cancer imparted in recent patents

Antiglaucoma agents revealed by French researchers

Agents for wound healing and pruritus described

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...